Twenty years of using economic evaluations for drug reimbursement decisions: What has been achieved?

Journal of Health Politics, Policy and Law

Volumn 38, Issue 6, 2013, Pages 1081-1102

  Drummond, Michael ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; COST; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HUMAN; NATIONAL HEALTH SERVICE; POLITICS; REIMBURSEMENT; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION MAKING; HEALTH CARE RATIONING; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; MODELS, ECONOMIC; POLITICS; PRESCRIPTION DRUGS; STATE MEDICINE;

EID: 84890854597     PISSN: 03616878     EISSN: 15271927     Source Type: Journal    
DOI: 10.1215/03616878-2373148     Document Type: Article

References (45)

1. Anell, A., and U. Persson. 2005. "Reimbursement and Clinical Guidance for Pharmaceuticals in Sweden: Do Health-Economic Evaluations Support Decision Making?" European Journal of Health Economics 6, no. 3: 274-79. doi:10.1007/s10198-005-0301-6.
2. Backhouse, M. E., et al. 2011. "Early Dialogue between the Developers of New Technologies and Pricing and Reimbursement Agencies: A Pilot Study." Value in Health 14, no. 4: 608-15. doi:10.1016/j.jval.2010.11.011.
3. Barbieri, M., N. Hawkins, and M. Sculpher. 2009. "Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision- Making about the Funding of Health Technologies." Value in Health 12, no. 2: 193-201. doi:10.1111/j.1524-4733.2008.00441.x.
4. Barbieri, M., et al., and the ISPOR Good Research Practices Economic Data Transferability Task Force. 2010. "What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?" Value in Health 13, no. 8: 1028-37. doi:10.1111/j.1524-4733.2010.00771.x.
5. Birch, S., and A. Gafni. 2007. "Economists'Dream or Nightmare? Maximizing Health Gains from Available Resources Using the NICE Guidelines." Health Economics, Policy, and Law 2, no. 2: 193-202. doi:10.1017/S1744133107004057.
6. Bryan, S., I. Williams, and S. McIver. 2007. "Seeing the NICE Side of Cost- Effectiveness Analysis: A Qualitative Investigation of the Use of CEA in NICE Technology Appraisals." Health Economics 16, no. 2: 179-93. doi:10.1002/hec.1133.
7. Cairns, J. 2006. "Providing Guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence Compared." Health Policy 76, no. 2: 134-43. doi:10.1016/j.healthpol.2005.05.006.
8. Canadian Agency for Drugs and Technologies in Health (CADTH). 2006. Guidelines for the Economic Evaluation of Health Technologies: Canada. Ottawa: CADTH.
9. Cleemput, I., et al. 2012. "European Drug Reimbursement Systems' Legitimacy: Five Country Comparison Tool." International Journal of Technology Assessment in Health Care 28, no. 4: 358-66. doi:10.1017/S0266462312000529.
10. Clement, F. M., et al. 2009. "Using Effectiveness and Cost-Effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada." Journal of the American Medical Association 302, no. 13: 1437-43. doi:10.1001/jama.2009.1409.
11. Commonwealth of Australia Department of Health and Ageing. 1992. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee, Including Submissions Involving Economic Analyses. Canberra: Australian Government Publishing Service.
12. Dakin, H. A., N. J. Devlin, and I. A. Odeyemi. 2006. "'Yes,' 'No' or 'Yes, But'? Multinomial Modelling of NICE Decision-Making." Health Policy 77, no. 3: 352-67. doi:10.1016/j.healthpol.2005.08.008.
13. Department of Health. 2010. A New Value-Based Approach to the Pricing of Branded Medicines: A Consultation. London: Department of Health.
14. Devlin, N., and D. Parkin. 2004. "Does NICE Have a Cost-Effectiveness Threshold and What Other Factors Influence Its Decisions? A Binary Choice Analysis." Health Economics 13, no. 5: 437-52. doi:10.1002/hec.864.
15. Drummond, M. F., et al. 2008. "Key Principles for the Improved Conduct of Health Technology Assessments for Resource Allocation Decisions." International Journal of Technology Assessment in Health Care 24: 244-58.
16. Eichler, H. G., et al. 2010. "Relative Efficacy of Drugs: An Emerging Issue between Regulatory Agencies and Third-Party Payers." Nature Reviews: Drug Discovery 9, no. 4: 277-91. doi:10.1038/nrd3079.
17. George, B., A. Harris, and A. Mitchell. 2001. "Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996)." PharmacoEconomics 19, no. 11: 1103-9. doi:10.2165/00019053-200119110-00004.
18. Hill, S. R., A. S. Mitchell, and D. A. Henry. 2000. "Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme." Journal of the American Medical Association 283, no. 16: 2116-21. doi:10.1001/jama.283.16.2116.
19. Hjelmgren, J., F. Berggren, and F. Andersson. 2001. "Health Economic Guidelines: Similarities, Differences, and Some Implications." Value in Health 4, no. 3: 225-50. doi:10.1046/j.1524-4733.2001.43040.x.
20. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 2011. Pharmacoeconomic Guidelines around the World. Lawrenceville, NJ: ISPOR. www.ispor.org/peguidelines/index.asp.
21. Jansen, J. P., et al., and the ISPOR Good Research Practices Task Force. 2011. "Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1." Value in Health 14, no. 4: 417-28. doi:10.1016/j.jval.2011.04.002.
22. Koopmanschap, M. A., E. A. Stolk, and X. Koolman. 2010. "Dear Policy Maker: Have You Made Up Your Mind? A Discrete Choice Experiment among Policy Makers and Other Health Professionals." International Journal of Technology Assessment in Health Care 26, no. 2: 198-204. doi:10.1017/S0266462310000048.
23. Landwehr, C. 2009. "Deciding How to Decide: The Case of Health Care Rationing." Public Administration 87, no. 3: 586-603.
24. Landwehr, C., and K. Böhm. 2011. "Delegation and Institutional Design in Health- Care Rationing." Governance 24, no. 4: 665-88. doi:10.1111/j.1468-0491.2011.01542.x.
25. Lexchin, J., and B. Mintzes. 2008. "Medicine Reimbursement Recommendations in Canada, Australia, and Scotland." American Journal of Managed Care 14: 581-88.
26. Lim, M. E., et al. 2010. "Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature." Value in Health 13, no. 2: 328-34. doi:10.1111/j.1524-4733.2009.00613.x.
27. Malin, J. L. 2010. "Wrestling with the High Price of Cancer Care: ShouldWe Control Costs by Individuals' Ability to Pay or Society's Willingness to Pay?" Journal of Clinical Oncology 28, no. 20: 3212-14. doi:10.1200/JCO.2010.28.9967.
28. Mason, A., et al. 2010. "Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?" Journal of Clinical Oncology 28, no. 20: 3234-38. doi:10.1200/JCO.2009.26.2758.
29. Mason, A. R., and M. F. Drummond. 2009. "Public Funding of New Cancer Drugs: Is NICE Getting Nastier?" European Journal of Cancer 45, no. 7: 1188-92. doi:10.1016/j.ejca.2008.11.040.
30. Mauskopf, J., et al. 2011. "Differences among Formulary Submission Guidelines: Implications for Health Technology Assessment." International Journal of Technology Assessment in Health Care 27, no. 3: 261-70. doi:10.1017/S0266462311000274.
31. Miners, A. H., et al. 2005. "Comparing Estimates of Cost Effectiveness Submitted to the National Institute for Clinical Excellence (NICE) by Different Organisations: Retrospective Study." British Medical Journal 330, no. 7482: 65-68. doi:10.1136/bmj.38285.482350.82.
32. Morgan, S., M. Barer, and R. Evans. 2000. "Health Economists Meet the Fourth Tempter: Drug Dependency and Scientific Discourse." Health Economics 9, no. 8: 659-67. doi:10.1002/1099-1050(200012)9:8 < 659::AID-HEC578 > 3.0.CO;2-0.
33. National Institute for Health and Clinical Excellence (NICE). 2011. "Our Guidance." www.nice.org.uk/.
34. Neumann, P. J. 2012. "What We Talk about When We Talk about Health Care Costs." New England Journal of Medicine 366, no. 7: 585-86. doi:10.1056/NEJMp1200390.
35. Nicod, E., and P. Kanavos. 2012. "Commonalities and Differences in HTAOutcomes: A Comparative Analysis of Five Countries and Implications for Coverage Decisions." Health Policy 108, nos. 2-3: 167-77. doi:10.1016/j.healthpol.2012.09.012.
36. O'Neill, P., and N. J. Devlin. 2010. "An Analysis of NICE's 'Restricted' (or 'Optimized') Decisions." PharmacoEconomics 28, no. 11: 987-93. doi:10.2165/11536970-000000000-00000.
37. Raftery, J. 2010. "Multiple Sclerosis Risk Sharing Scheme: A Costly Failure." British Medical Journal 340: c1672. doi:10.1136/bmj.c1672.
38. Rawlins, M. D., and A. J. Culyer. 2004. "National Institute of Clinical Excellence and Its Value Judgments." British Medical Journal 329, no. 7459: 224-27. doi:10.1136/bmj.329.7459.224.
39. Sculpher, M. J., and M. F. Drummond. 2006. "Analysis sans Frontières: CanWe Ever Make Economic Evaluations Generalisable across Jurisdictions?" Pharmaco- Economics 24, no. 11: 1087-99. doi:10.2165/00019053-200624110-00006.
40. Sheldon, T. A., et al. 2004. "What's the Evidence That NICE Guidance Has Been Implemented? Results from a National Evaluation Using Time Series Analysis, Audit of Patients' Notes and Interviews." British Medical Journal 329, no. 7473: 999. doi:10.1136/bmj.329.7473.999.
41. Sorenson, C., M. F. Drummond, and K. Chalkidou. 2012. "Comparative Effectiveness Research: The Experience of the National Institute for Health and Clinical Excellence." Journal of Clinical Oncology 30, no. 34: 4267-74. doi:10.1200/JCO.2012.42.1974.
42. Sorenson, C., M. F. Drummond., P. Kanavos. 2008. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union. Observatory Studies Series No. 11. Cornwall, UK: MPG Books.
43. Tappenden, P., et al. 2007. "A Stated Preference Binary Choice Experiment to Explore NICE Decision Making." PharmacoEconomics 25, no. 8: 685-93. doi:10.2165/00019053-200725080-00006.
44. Towse, A. 2010. "Value Based Pricing, Research and Development, and Patient Access Schemes: Will the United Kingdom Get It Right or Wrong?" British Journal of Clinical Pharmacology 70, no. 3: 360-66. doi:10.1111/j.1365-2125.2010.03740.x.
45. Walker, D. G., et al. 2012. Best Practices for Conducting Economic Evaluation in Health Care: A Systematic Review. Publication no. 12(13)-EHC132-EF. Rockville, MD: Agency for Health Services Research and Policy.